Scholarlink

Introduction <p>Hypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain.</p> Methods <p>GPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ≥ 6&#xa0;months in primary care. Participants underwent 14&#xa0;days of blinded CGM (FreeStyle Libre<sup>®</sup> Pro iQ<sup>®</sup>). The primary objective of the present study was to estimate the proportion of patients with T2DM treated with Gla-100 whose TBR (glucose &lt; 70&#xa0;mg/dL) exceeded the internationally recommended threshold of 4%. Secondary endpoints included time in range (TIR), time above range (TAR), episodes of clinically significant hypoglycemia (&lt; 54&#xa0;mg/dL), cognitive function (MMSE), and fear of hypoglycemia (EsHFS).</p> Results <p>Among 136 patients (mean age 69&#xa0;years), 16.9% had TBR &gt; 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (&lt; 54&#xa0;mg/dL &gt; 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent &gt; 25% of the day between 181–250&#xa0;mg/dL, and 28.7% spent time &gt; 250&#xa0;mg/dL. Only 55.9% achieved TIR ≥ 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE &lt; 23) was associated with longer hypoglycemia duration.</p> Conclusions <p>Blinded CGM revealed a relevant burden of unrecognized hypoglycemia—particularly nocturnal—as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Virginia Bellido,
  • Ana Cebrián,
  • Cristóbal Morales,
  • Alberto S. de las Hazas,
  • Alfonso Soto-Gonzalez,
  • Carla Morer-Liñan,
  • José M. Borrachero,
  • Gabriel Cuatrecases,
  • Elena L. García,
  • Judith López-Fernández,
  • Silvia Lozano-García,
  • Álvaro M. Bayón,
  • Cristina M. Niño-Azcarate,
  • Oscar Laclaustra,
  • Paulina Fuentealba

摘要

Introduction

Hypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain.

Methods

GPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ≥ 6 months in primary care. Participants underwent 14 days of blinded CGM (FreeStyle Libre® Pro iQ®). The primary objective of the present study was to estimate the proportion of patients with T2DM treated with Gla-100 whose TBR (glucose < 70 mg/dL) exceeded the internationally recommended threshold of 4%. Secondary endpoints included time in range (TIR), time above range (TAR), episodes of clinically significant hypoglycemia (< 54 mg/dL), cognitive function (MMSE), and fear of hypoglycemia (EsHFS).

Results

Among 136 patients (mean age 69 years), 16.9% had TBR > 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (< 54 mg/dL > 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent > 25% of the day between 181–250 mg/dL, and 28.7% spent time > 250 mg/dL. Only 55.9% achieved TIR ≥ 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE < 23) was associated with longer hypoglycemia duration.

Conclusions

Blinded CGM revealed a relevant burden of unrecognized hypoglycemia—particularly nocturnal—as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.